On 30 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana, Phase IIa (NCT06771115) trial results were presented for Ventyx Biosciences’ VTX3232 (parunoflast), which was evaluated alone or in combination with semaglutide in patients with obesity.
VTX3232 is a potent, selective brain-penetrating inhibitor of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), administered once daily as an oral therapy. It is currently in Phase II of development in the US for Parkinson’s disease and obesity-associated cardiometabolic diseases.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
The trial was a 12-week multi-centre, randomised, double-blind, placebo-controlled study, comprised four arms: placebo once-daily (QD), VTX3232 30mg QD, placebo QD with semaglutide once-weekly (QW), and VTX3232 mg QD with semaglutide QW. The primary endpoints assessed the safety and tolerability profile of VTX3232, including the incidence and severity of adverse events (AEs) and severe adverse events (SAEs). Secondary endpoints included the change from baseline in high-sensitivity C-reactive protein (hsCRP). Furthermore, the trial assessed the change from baseline in body weight, inflammatory and NLRP3 pathway biomarkers, and liver fat and liver inflammation.
VTX3232 met its primary endpoints, demonstrating an acceptable safety and tolerability profile. A single treatment-emergent adverse event (TEAE) resulting in study discontinuation was observed in both the VTX3232 30 mg QD and VTX3232 20mg QD with semaglutide QW arms, and one SAE was reported in the VTX3232 30mg QD group; notably, no SAEs were considered related to the study drug across any arm. Secondary endpoints were also met, with VTX3232 producing a rapid and sustained reduction in hsCRP. Additionally, VTX3232 reduced interleukin-6 (IL-6), fibrinogen, erythrocyte sedimentation rate (ESR), and lipoprotein(a), and decreased liver inflammation independent of anti-steatotic effects. However, no significant impact on body weight was observed.
Whilst the data does not position VTX3232 as a standalone treatment for obesity, the agent demonstrates meaningful reductions in systemic and hepatic inflammation, both as a monotherapy and in combination with semaglutide, addressing the residual inflammatory burden that persists in obesity beyond weight loss alone.
Key opinion leaders (KOLs) interviewed by GlobalData have identified improved tolerability of obesity medications as an ongoing unmet need, particularly with respect to reducing treatment-related side effects.
VTX3232 continues to demonstrate a differentiated profile within the obesity-associated cardiometabolic space, with its anti-inflammatory mechanism offering a complementary approach to existing weight-loss therapies. According to GlobalData’s Pharma Intelligence Center, there are 48 Phase III candidates, 109 Phase II candidates, and 155 Phase I candidates for overweight and obesity globally.
